Sufentanil

Sufentanil
Clinical data
Trade names	Dsuvia, Sufenta, Zalviso, others
Other names	R30730
AHFS/Drugs.com	Monograph
License data	US DailyMed: Sufentanil;
Routes of; administration	Intravenous therapy (IV), intramuscular injection (IM), subcutaneous injection (SQ), epidural, intrathecal, sublingual
ATC code	N01AH03 (WHO) ;
Legal status
Legal status	AU: S8 (Controlled drug); BR: Class A1 (Narcotic drugs); CA: Schedule I; DE: Anlage III (Special prescription form required); UK: Class A; US: Schedule II; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Sublingual: 53% IV/IM/SC: 100%
Elimination half-life	162 minutes
Duration of action	30 to 60 min
Identifiers
	IUPAC name N-[4-(Methoxymethyl)-1-(2-thiofuran-2-ylethyl)-4-piperidyl]-N-phenylpropanamide;
CAS Number	56030-54-7 ;
PubChem CID	41693;
IUPHAR/BPS	3534;
DrugBank	DB00708 ;
ChemSpider	38043 ;
UNII	AFE2YW0IIZ;
KEGG	D05938 ; as salt: D00845 ;
ChEBI	CHEBI:9316 ;
ChEMBL	ChEMBL658 ;
CompTox Dashboard (EPA)	DTXSID6023604 ;
ECHA InfoCard	100.168.858
Chemical and physical data
Formula	C22H30N2O2S
Molar mass	386.55 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	97 °C (207 °F)
	SMILES O=C(N(c1ccccc1)C2(COC)CCN(CC2)CCc3sccc3)CC;
	InChI InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3 ; Key:GGCSSNBKKAUURC-UHFFFAOYSA-N ;
	(verify)

Sufentanil, sold under the brand names Sufenta among others, is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 to 1,000 times as potent as morphine. Structurally, sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring (which increases potency but is believed to reduce duration of action), and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.